FinnCap reiterated their buy rating on shares of Motif Bio (LON:MTFB) in a report issued on Wednesday, November 22nd, StockTargetPrices.com reports. The firm currently has a GBX 100 ($1.35) target price on the stock.
Other research analysts have also issued reports about the stock. Northland Securities reaffirmed a buy rating on shares of Motif Bio in a research note on Wednesday, August 9th. Beaufort Securities reiterated a speculative buy rating and issued a GBX 110 ($1.48) target price on shares of Motif Bio in a report on Thursday, November 16th. Finally, Peel Hunt reiterated a buy rating and issued a GBX 106 ($1.43) target price on shares of Motif Bio in a report on Wednesday, November 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Motif Bio currently has a consensus rating of Buy and an average target price of GBX 101.50 ($1.37).
Shares of Motif Bio (MTFB) traded down GBX 0.75 ($0.01) during midday trading on Wednesday, reaching GBX 35 ($0.47). 400,820 shares of the company traded hands, compared to its average volume of 1,200,000. Motif Bio has a fifty-two week low of GBX 22 ($0.30) and a fifty-two week high of GBX 51.75 ($0.70).
TRADEMARK VIOLATION NOTICE: “FinnCap Reaffirms “Buy” Rating for Motif Bio (MTFB)” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2017/12/07/motif-bio-plc-mtfb-receives-buy-rating-from-finncap-updated-updated.html.
Motif Bio Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio plc and related companies with MarketBeat.com's FREE daily email newsletter.